Arjan Diepstra
dr.
As a hematopathologist, I work on diagnostics of all types of hematological malignancies using a comprehensive panel of different techniques. Moreover, my main research interest involves Hodgkin lymphoma, with a strong focus on interactions between tumor cells and the microenvironment. In addition, I also have a long standing interest in genetic susceptibility. My areas of expertise are: immunology, tumor cell biology, genetic association studies and molecular diagnostics in pathology. I actively participate in international (EORTC) and national (HOVON) clinical trials.
Latest publications
(216)
Activities
(38)
Press/Media
(7)
Prizes
(4)
Datasets
(1)
Supervised work
(12)
Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC
Published in: British Journal of Haematology
Access to document
10.1111/bjh.14317
Soluble Galectin-1 (sGal-1, also termed LGALS1), soluble CD163 (sCD163) and soluble CD30 (sCD30) have been reported to be elevated in plasma or serum of patients with classical Hodgkin lymphoma (cHL). We aimed to determine the clinical utility of these biomarkers for evaluation of treatment response compared to thymus and activation regulated chemokine (TARC, also termed CCL17). Plasma or serum samples were prospectively collected among 103 newly diagnosed cHL patients before and after treatment. Levels of sGal-1, sCD163, sCD30 and TARC were correlated with disease characteristics and clinical treatment...
Wouter J. Plattel, Zainab N. D. Alsada, Gustaaf W. van Imhoff, Arjan Diepstra, Anke van den Berg, Lydia Visser
Progression of a solitary plasmacytoma to multiple myeloma. A population-based registry of the northern Netherlands
Published in: British Journal of Haematology
Access to document
10.1111/bjh.14291
document
Plasmacytoma is characterized by a local accumulation of monoclonal plasma cells without criteria for multiple myeloma (MM). The current treatment regimen is local radiotherapy. However, more than 50% of patients develop MM within 2years after treatment. A population-based registry was consulted for the diagnosis of solitary plasmacytoma between 1988 and 2011. Progression to MM and prognostic features for progression to MM were scored, including hypoxia inducible factors (HIF), vascular endothelial growth factor (VEGF, also termed VEGFA) and micro-vessel density (MVD) expression in biopsy material. A total of 76...
Esther G. M. de Waal, Marnix Leene, Nic Veeger, Hanneke J. Vos, Francisca Ong, Wilma G. J. M. Smit, Sjoerd Hovenga, Mels Hoogendoorn, Marieke Hogenes, Max Beijert, Arjan Diepstra, Edo Vellenga
Studying the role of oncogenic mir-24-3p in hodgkin lymphom
Y. Yuan, J. Kluiver, J. Koerts, D. de Jong, Bea Rutgers, A. Diepstra, Lydia Visser, Anke Berg, van den
Mutations in CD58 and MYB in Hodgkin Lymphoma
F.R. Abdul Razak, A. Diepstra, D. Jong, J. Koerts, B. Rutgers, J. Kluiver, Lydia Visser, Anke Berg, van den
Mid-treatment TARC and mid-treatment FGD-PET predict for progression free survival in classical hodgkin lymphom